Cefoxitin could be an alternative to carbapenems in extended-spectrum-beta-lactamase-producing Escherichia coli (ESBL-EC) infections.
However, pharmacological and clinical data regarding cefoxitin are limited. Using a recent pharmacological model and the MICs of ESBL-EC collected from pyelonephritis, we determined the probabilities to reach four pharmacological targets: free cefoxitin concentrations above the MIC during 50% and 100% of the administration interval (T>MIC = 50% and T>MIC = 100%, respectively) and free cefoxitin concentrations above 4× MIC during 50% and 100% of the administration interval (T>4MIC = 50% and T>4MIC = 100%, respectively). Cefoxitin could be used to treat ESBL-EC pyelonephritis, but administration modalities should be optimized according to MICs in order to reach pharmacological targets.
Written by:
Guet-Revillet H, Emirian A, Groh M, Nebbad-Lechani B, Weiss E, Join-Lambert O, Bille E, Jullien V, Zahar JR. Are you the author?
Université Paris Descartes, Paris, France Service de Microbiologie-Hygiène Hospitalière, Hôpital Necker-Enfants-Malades, AP-HP, Paris, France; Service de Bactériologie, Virologie, Hygiène, Hôpital Henri-Mondor, AP-HP, Créteil, France Université Paris-Est, Créteil, France; Service de Microbiologie-Hygiène Hospitalière, Hôpital Necker-Enfants-Malades, AP-HP, Paris, France; Service de Pharmacologie Clinique, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; INSERM U1129, Paris Descartes, Paris, France.
Reference: Antimicrob Agents Chemother. 2014 Aug;58(8):4899-901.
doi: 10.1128/AAC.02509-14
PubMed Abstract
PMID: 24777104